A phase I open label study of fostamatinib, a SYK inhibitor, in patients with lower-risk myelodysplastic syndrome and chronic myelomonocytic leukemia.
Saved in:
| Title: | A phase I open label study of fostamatinib, a SYK inhibitor, in patients with lower-risk myelodysplastic syndrome and chronic myelomonocytic leukemia. |
|---|---|
| Authors: | Croden, J.1 (AUTHOR), Garcia-Manero, G.1 (AUTHOR), Chien, K.1 (AUTHOR), DiNardo, C.1 (AUTHOR), Borthakur, G.1 (AUTHOR), Hammond, D.1 (AUTHOR), Bose, P.1 (AUTHOR), Short, N.1 (AUTHOR), Romero, L.1 (AUTHOR), Shneider, H.1 (AUTHOR), Hatfield, M.1 (AUTHOR), Pierce, S.1 (AUTHOR), Huang, X.2 (AUTHOR), Hwang, H.2 (AUTHOR), Montalban-Bravo, G.1 (AUTHOR) GMontalban1@mdanderson.org |
| Source: | Leukemia & Lymphoma. Jun2026, Vol. 67 Issue 7, p1580-1586. 7p. |
| Database: | Academic Search Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 10428194 |
|---|---|
| DOI: | 10.1080/10428194.2026.2650674 |
